MetaCap

Bicara Therapeutics (BCAX) vs Geron (GERN)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Geron (GERN) has outperformed Bicara Therapeutics (BCAX) over the past year, losing 22.3% versus a loss of 53.2%. Geron is the larger company by market cap ($560.9 million vs $560.3 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

BCAX-53.22%GERN-22.26%
+81%+9%-63%
Nov 21, 20251 yearNov 20, 2026
BCAX-63.95%GERN-80.69%
+29%-28%-86%
Sep 9, 20245 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

BCAX versus GERN key metrics
MetricBCAXGERN
Share price$8.44$0.8707
Market cap$560.31M$560.94M
1-day change-7.46%-4.63%
YTD return-49.85%-34.04%
1-year return-53.22%-22.26%
5-year return—-40.77%
Forward P/E—9.67
EPS (TTM)$-3.46$-0.08
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Net income (latest FY)$-137.95M$-83.50M
52-week high$30.99$2.01
52-week low$7.87$0.84
Distance from 52-week high-72.77%-56.68%
Analyst consensusstrong_buybuy
Avg. price target upside+281.16%+301.98%
Average volume1.20M13.05M
Shares outstanding66.39M644.24M
Employees103258
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • GERN has outperformed BCAX by 31.0 percentage points over the past year.

About Bicara Therapeutics

BCAX stock →

Bicara Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the development of bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines a clinically validated epidermal growth factor receptor directed monoclonal antibody bound to human transforming growth factor beta for the treatment of solid tumors.

Health Care · Biotechnology: Pharmaceutical Preparations · 103 employees

About Geron

GERN stock →

Geron Corporation, a commercial-stage biopharmaceutical company, focuses on the development of therapeutics products for oncology. The company's product pipeline includes RYTELO, a telomerase inhibitor for the treatment of adult patients with low- to intermediate-1 risk myelodysplastic syndromes with transfusion-dependent anemia; IMerge which is in Phase 3 clinical trial for the treatment of lower-risk myelodysplastic syndromes; IMpactMF that is in Phase 3 for the treatment of relapsed/refractory myelofibrosis; Impress which is in Phase 2 clinical trial to treat higher risk myelodysplastic syndromes and acute myeloid leukemia (AML); IMproveMF which is in Phase 1 clinical trial for the treatment of frontline myelofibrosis; and IMAGINE which is in phase 1/2 clinical trial for the treatment of relapsed/refractory AML.

Health Care · Biotechnology: Pharmaceutical Preparations · 258 employees

BCAX vs GERN FAQ

Which is bigger, Bicara Therapeutics or Geron?

Geron (GERN) is larger, with a market capitalization of $560.94M compared with $560.31M for Bicara Therapeutics (BCAX).

Which stock has performed better over the past year, BCAX or GERN?

GERN returned -22.26% over the past 12 months, compared with -53.22% for BCAX (price return, excluding dividends). Past performance does not predict future results.

Are Bicara Therapeutics and Geron in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons